As of the latest Form 4 filed Jun 18, 2026.
What Ocular Therapeutix Inc insiders — officers, directors and 10% owners — have bought and sold in their own stock, straight from their SEC Form 4 filings. Values are shares × the reported transaction price where both are disclosed.
Buys plotted up, sells down; bar height is the disclosed dollar value (shares × reported price). Our Form 4 history is only complete from mid-2026, so early months are sparse — the series fills in as more filings land. Open-market purchases and sales only.
Newest filing first — the 21 most recent filings for OCUL.
| Filed | Trade date | Insider | Transaction | Shares | Price | Value | 10b5-1 | Filing |
|---|---|---|---|---|---|---|---|---|
| 2026-06-18 | 2026-06-16 | Dugel Pravin See Remarks | GGift | +50.1K | $0.00 | $0.00 | No | Form 4 ↗ |
| 2026-06-18 | 2026-06-16 | Dugel Pravin, See Remarks | GGift | −50.1K | $0.00 | $0.00 | No | Form 4 ↗ |
| 2026-06-12 | 2026-06-10 | Warden Charles M Director | AAward | +14.0K | $0.00 | $0.00 | No | Form 4 ↗ |
| 2026-06-12 | 2026-06-10 | Graves Adrienne L Director | AAward | +14.0K | $0.00 | $0.00 | No | Form 4 ↗ |
| 2026-06-12 | 2026-06-10 | Robins Jason Shand Chief Financial Officer | AAward | +15.4K | $0.00 | $0.00 | No | Form 4 ↗ |
| 2026-06-12 | 2026-06-10 | Hong Seung Suh Director | AAward | +14.0K | $0.00 | $0.00 | No | Form 4 ↗ |
| 2026-06-12 | 2026-06-10 | LINDSTROM RICHARD L MD Director | AAward | +14.0K | $0.00 | $0.00 | No | Form 4 ↗ |
| 2026-06-12 | 2026-06-10 | RAINES MERILEE Director | AAward | +14.0K | $0.00 | $0.00 | No | Form 4 ↗ |
| 2026-06-12 | 2026-06-10 | Williams Leslie J. Director | AAward | +14.0K | $0.00 | $0.00 | No | Form 4 ↗ |
| 2026-06-05 | 2026-06-03 | Waheed Nadia Chief Medical Officer | SSale | −14.8K | $8.27 | $123K | Yes (planned) | Form 4 ↗ |
| 2026-05-28 | 2026-05-28 | Dugel Pravin See Remarks | GGift | +395K | $0.00 | $0.00 | Yes (planned) | Form 4 ↗ |
| 2026-05-28 | 2026-05-28 | Dugel Pravin, See Remarks | GGift | −395K | $0.00 | $0.00 | Yes (planned) | Form 4 ↗ |
| 2026-05-28 | 2026-05-26 | Dugel Pravin, See Remarks | SSale | −21.2K | $8.20 | $173K | Yes (planned) | Form 4 ↗ |
| 2026-05-28 | 2026-05-26 | Kaiser Peter Chief Development Officer | SSale | −2.97K | $8.20 | $24.3K | Yes (planned) | Form 4 ↗ |
| 2026-05-28 | 2026-05-26 | Heier Jeffrey S. Chief Scientific Officer | SSale | −3.02K | $8.20 | $24.7K | Yes (planned) | Form 4 ↗ |
| 2026-05-28 | 2026-05-26 | Nayak Sanjay Chief Strategy Officer | SSale | −1.86K | $8.20 | $15.2K | Yes (planned) | Form 4 ↗ |
| 2026-04-13 | 2026-04-09 | Dugel Pravin See Remarks | GGift | +395K | $0.00 | $0.00 | No | Form 4 ↗ |
| 2026-04-13 | 2026-04-09 | Dugel Pravin, See Remarks | GGift | −395K | $0.00 | $0.00 | No | Form 4 ↗ |
| 2026-02-04 | 2026-02-04 | Notman Donald Chief Operating Officer | SSale | −6.04K | $8.54 | $51.5K | No | Form 4 ↗ |
| 2026-02-04 | 2026-02-02 | Notman Donald, Chief Operating Officer | SSale | −5.46K | $9.14 | $49.9K | No | Form 4 ↗ |
| 2026-01-26 | 2026-01-21 | Robinson David Wayne Global CCO | AAward | +136K | $0.00 | $0.00 | No | Form 4 ↗ |
Insiders — a company’s officers, directors and holders of more than 10% of its stock — must report any trade in that stock to the SEC on a Form 4 within two business days. Each row here is one transaction from those filings.
The transaction code tells you what happened: Purchase (P) and Sale (S) are open-market trades — the ones markets watch most; Award (A) is a granted stock or unit, Option exercise (M) converts options into shares, and Gift (G) is a transfer for no consideration. Awards, exercises and gifts are largely compensation or administrative, not a directional bet.
One caveat on sales: many are made under a Rule 10b5-1 plan scheduled months in advance, so a sale is not automatically a bearish signal. Insider activity is a noisy input — read it alongside the filings, not on its own.
See also OCUL’s full analysis or the market-wide insider trading feed. The tabs above jump to OCUL’s other SEC data.
Source: SEC Form 4 filings for OCUL, parsed from EDGAR. Transaction prices are as reported in the filing — SEC public-domain data, not market quotes. Values are shares × reported price where both are disclosed; grants and gifts often carry no price. A delayed record of what insiders reported, not a live position or a recommendation.
Research and education only — not financial advice. TENKis not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities TENK rates; see Disclosures. Past performance does not guarantee future results. Do your own research.